- Company
- COVID-19 devastates outpatient prescription in April-May
- by Chon, Seung-Hyun Jun 25, 2020 06:07am
- Top pharmaceutical companies have been struggling with outpatient prescription sales for two consecutive months. The COVID-19 seems to have slowed down drug prescription for nine out of ten major pharmaceutical companies in last two months and impacted the overall prescription volume this year. On June 22, pharmaceutical market research firm
- Policy
- The addition of Lipiodol will end in next May
- by Kim, Jung-Ju Jun 24, 2020 11:07am
- Lipiodol (Iodized oil) was lowered by 30% due to the government's authority adjustment, and was confirmed until the end of the addition. This is because Fattiodol by Dongkook has been released. Anagre by Yuhan and Agrylin by Shire Plc have secured the same number of products, and the surplus, which has been retained since the end of the secon
- Company
- COVID-19's budget is being delayed in the National Assembly
- by Nho, Byung Chul Jun 24, 2020 06:14am
- With the global spread of COVID-19, vaccines and treatments are urgently needed, and the government's promised support budget plan is not in progress. Unlike the fast and full support in developed countries, there is concern that the support may be delayed and the golden time to overcome COVID-19 may be missed. As of the 23rd, 15 dome
- Company
- Penmix in trial to evade patent on fat dissolving Belkyra
- by Nho, Byung Chul Jun 24, 2020 06:14am
- An injection CDMO Penmix (CEO Park Dongkyu) succeeded in evading patent on Allergan’s under-chin fat reducing injection Belkyra (desoxycholic acid). On June 19, Intellectual Property Trial and Appeal Board validated the negative confirmation of patent scope on Belkyra’s desoxycholic acid and other pharmaceutical substance based on the
- Policy
- Promote to fast track bill for innovative companies
- by Lee, Jeong-Hwan Jun 24, 2020 06:14am
- Legislation is being put in place to give special cases of 'fast tracks' that speed up the approval and review process for new drugs developed by innovative pharmaceutical companies. The goal is to revitalize new drug development, grow innovation, and create jobs. On the 22nd, Ki Dongmin, a member of Democratic Party of Korea announced
- Policy
- Reimbursement cut on prescribing multiple low-dose Verzenio
- by Lee, Hye-Kyung Jun 24, 2020 06:13am
- The healthcare benefit would be cut for prescribing multiple unit of Lilly Korea’s Verzenio 50 mg, instead of 100 mg or 150 mg doses. Both of Verzenio’s low and high-dose tablets are priced at 49,587 won, and more reimbursement is paid out on prescribing two 50 mg tablets instead or one 100 mg tablet or prescribing three 50 mg tablets
- Company
- Patients with Ultracet don't get benefit for anticancer drug
- by Eo, Yun-Ho Jun 23, 2020 06:21am
- There have been cases that do not meet the intention of the original insurance benefit standard in the treatment of prostate cancer. Targeted anticancer drug options such as 'Zytiga (Abiraterone acetate)' and 'Xtandi (Enzalutamide)' currently exist in adult resistant castration resistant prostate cancer (mCRPC). Moreover, since last May, t
- Policy
- HIRA clarifies coverage standard of Imfinzi following CCRT
- by Lee, Hye-Kyung Jun 23, 2020 06:21am
- To receive healthcare reimbursement when using AstraZeneca’s immunotherapy Imfinzi (durvalumab), a patient has to receive platinum-based concurrent chemoradiotherapy (CRT). Affected patients should be aware that the reimbursement benefit would not be provided for using Imfinzi after using sequential CRT or induction chemotherapy. K
- Company
- Immunotherapies tap on SCLC treatment area for more options
- by Eo, Yun-Ho Jun 23, 2020 06:21am
- One after another, immunotherapies are tapping into the unexplored small cell lung cancer (SCLC) treatment area. According to the pharmaceutical industry sources on June 20, AstraZeneca’s Imfinzi (duvalumab), following Tecentriq (atezolizumab) by Roche, has been indicated as a first-line treatment for SCLC by Korea’s Ministry of Food
- Policy
- Minister Choi said, COVID-19 treatment may come out
- by Lee, Jeong-Hwan Jun 23, 2020 06:20am
- Choi Kiyoung, Minister of Science and ICT, said that as soon as possible, COVID-19 treatment could be developed within two months. Minister Choi said that the development of treatments through the ‘drug repositioning method’ to discover the effect of COVID-19 treatment of already-approved drugs has been revealed, not through the approval
